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INTRODUCTION
Large-scale clinical studies and an updated meta-analysis 
comprehensively described the performance of cfDNA test-
ing for the common trisomies—21, 18, and 13—and, to a 
lesser extent, for sex-chromosome anomalies (SCAs).1–4 
Independent lines of converging evidence suggest that 
a substantial fraction of clinically relevant aneuploidies 
is neglected by such a restricted detection scheme: (i) the 
common trisomies comprise only approximately 75% of 
aneuploidies detected by karyotyping in Down syndrome 
screen-positive cases, with 85% including the SCAs5; (ii) reg-
istry data showed that 17% of clinically relevant anomalies 
would go undetected6; and (iii) a review of 4,000 prenatal 
karyotype results revealed that 24% of the reported anoma-
lies would have been overlooked.7
The main aneuploidy classes ignored by the current genera-
tion of cfDNA screening methods comprise the rare autosomal 
trisomies (RATs) and the structural chromosome anomalies, 
specifically disease-causing copy-number variations (CNVs). 
Both types of aberrations generate positive results in conven-
tional aneuploidy screening used to prescribe cfDNA testing. 
In fact, first-trimester screening for T21, T18, and T13 is also 
sensitive to a broad range of RATs and chromosomal mosa-
icism.8 Chromosomal microarray platforms provide an incre-
mental diagnostic yield of 5% in fetuses with increased nuchal 
translucency (NT) diagnosed by first-trimester ultrasound and 
a normal karyotype.9
Independent follow-up of pregnancies considered unaffected 
by such cfDNA tests confirmed that rare pathogenic aneuploi-
dies such as T22 mosaicism are overlooked.10 Given the signifi-
cant incidence of mosaic aneuploidy,11,12 and the fact that the 
knowledge base on rare trisomy mosaicism has considerably 
increased,13 routine detection of such anomalies in mainstream 
cfDNA clinical practice becomes an option. Moreover, the phe-
notypic impact of RATs reaches beyond fetal mosaic trisomies; 
after trisomy or monosomy rescue, uniparental disomy (UPD) 
can cause fetal pathology, even in diploid fetuses when chro-
mosomes undergoing imprinting are involved.12,14 Placental 
trisomies account for a low but significant risk of intrauterine 
growth restriction, and for an even higher risk of small-for- 
gestational-age infants.15
The population history16 and morbidity maps17 of dele-
tion and duplication CNVs have been extensively described. 
It has been estimated that CNVs >400 kb account for almost 
15% of disease burden in children affected by intellectual dis-
ability and congenital anomalies.17 A meta-analysis confirmed 
the incremental diagnostic yield of performing chromosomal 
microarray analysis for cases of increased NT after first-tri-
mester ultrasound.9 Implementation of routine CNV detection 
using cfDNA sequencing posed challenges, however. Initial 
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studies suggested that higher genomic coverage was required 
to detect CNVs.18,19 Also, experimental protocols that robustly 
detect defined CNV size classes that take the fetal fraction into 
account and use genomic coverage similar to that of numerical 
anomalies were not available until recently.20 A clinical follow-
up study effectively showed that cfDNA testing can be extended 
to include reliable detection of deletion CNVs.21
We previously described a technical validation study using 
cfDNA screening with low genomic coverage that robustly 
detected a broader array of anomalies comprising the common 
trisomies, the SCAs, the RATs, and deletion and duplication 
CNVs.22 The algorithms were optimized for uniformly reliable 
detection of numerical autosomal and sex-chromosome anom-
alies and CNVs, in a manner similar to procedures described in 
a recent report.23
Here, we review a series of 6,388 consecutive singleton 
pregnancies with nearly complete and stratified follow-up; we 
tested the extended range of anomalies. Moreover, fetal frac-
tion measurements and a fetal cfDNA enrichment procedure 
were integrated. The latter was used in conjunction with signal 
intensity/z-scores to determine the main sources of false-nega-
tive results (low fetal fraction and true fetal mosaicism/TFM5), 
to predict maternally inherited numerical SCAs and CNVs, 
to stratify the likelihood of true-positive versus false-positive 
results, and to establish the detection threshold for recurrent 
pathogenic CNVs. We issue recommendations for clinical 
implementation of such a detection scheme on a broader scale.
MATeRIALs AND MeTHODs
study design
The consecutive cases consisted of two nonoverlapping data 
sets. The first aimed at complete follow-up of newborns based 
on the predicted birth of all pregnancies included, and the sec-
ond aimed at evaluating the effects of integrating the routine 
measurement of the fetal fraction. The fetal fraction (methodol-
ogy described in the supplementary section) was retroactively 
assessed for the first set. All surviving pregnancies of the sec-
ond set were born. The principal outcomes were the accurate 
classification of singleton pregnancies as euploid and aneu-
ploid and the follow-up of pregnancies with invasive testing/
amniocentesis for aneuploidies considered aberrant/abnormal, 
likely aberrant/abnormal, or of unknown clinical significance 
(UNK). Clinical outcomes were ascertained at birth for euploid 
results considered normal, likely normal, and UNK. The fol-
low-up was stratified. The proportion of cases followed-up with 
amniocentesis performed by internal or external cytogenetics 
laboratories increased with increasing uncertainty about the 
abnormality status. Pregnancy outcomes were monitored by 
using online registries for verified aneuploidies and for birth 
outcomes based on voluntary information provided by physi-
cians, by inquiring about the birth outcomes of two sets of 250 
random samples in the two main linguistic regions, and by con-
sulting with other physicians. The classification of test results 
is described in the Supplementary Materials and Methods 
online.
samples, cfDNA aneuploidy screening, fetal cfDNA 
enrichment, data sets, and patients
Ethylenediaminetetraacetic acid blood tubes (Becton 
Dickinson, Sarstedt, Germany) were used because of regula-
tory requirements (CE marking). Exclusion criteria were as 
follows: transportation time >48 h, total DNA concentrations 
≥4 ng/μl, and visible hemolysis (degree defined by photo-
graphic references). The cfDNA extracted from 1 ml of plasma 
was analyzed by shotgun sequencing on Illumina sequencers 
(HighSeq 2000),22 with a minimal genomic coverage of 0.0156-
fold (≥10 × 106 unique exact 50-nt sequence tags). Fetal cfDNA 
enrichment was obtained by removing fragments >200 nt by 
gel electrophoresis (methodology described in supplementary 
section). Two consecutive data sets based on test reports by 
board-certified laboratory geneticists were retrieved from the 
clinical database: one for the period beginning in March 2013 
through August 2014 and one from the beginning of September 
2014 through May 2015, which was after the integration of the 
routine measurement of the fetal fraction.
The first data set included 4,545 pregnancies (4,497 singleton 
and 48 twin pregnancies) the second included 1,843 samples 
(not overlapping with the first set). The results for annotated 
singleton pregnancies were used as the basis for the statistics 
after one additional review by an independent expert geneticist. 
Samples with fetal fractions <3% were excluded and a second 
blood draw was requested.
ResULTs
Readout and follow-up
Overall, 258/6,388 (4.04%) samples were considered abnormal 
or likely abnormal (Figure 1), comprising 119 common triso-
mies (1.86%), 53 SCAs (0.83%), 50 RATs (0.78%), and 36 CNVs 
(0.56%). Conversely, 6,130 samples (95.96%) were considered 
normal or likely normal. Details on the sample and patient 
characteristics can be found in the Supplementary Results 
online section.
The 119 common trisomies were invariably classified as 
abnormal or likely abnormal and comprised 84 T21 (70.6%), 
Figure 1 The detected aneuploidy classes. The absolute numbers of 
the aneuploidy classes are shown from left to right: the common trisomies 
(trisomy 21, 18, and 13), the sex-chromosome anomalies (monosomy X, 
triple X, and Klinefelter syndromes), the rare autosomal trisomies, and the 
deletion and duplication copy-number variations.
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19 T18 (T18; 16%), and 16 T13 samples (13.4%). Fifteen addi-
tional samples were rated as UNK (0.23%). Discriminating 
between euploid and aneuploid was simple for T21 because 
75/84 (89.3%) z-scores were at least 1.5 times higher than the 
threshold. All but three results (81/84; 97.6%) were considered 
aberrant—these three were rated likely aberrant—and three 
were classified as UNK. Trisomy 18 scores were also generally 
high (≥1.5× threshold z-score) for 16/19 (84.2%), with 18/19 
rated abnormal and 1 rated likely abnormal, but a higher num-
ber, 8 overall, were considered UNK. Twelve out of 16 T13 
results (75%) had high scores (≥1.5× threshold z-score), 15/16 
were aberrant, 1 was likely aberrant, and 4 were considered 
UNK.
Follow-up with amniocentesis was 47% for the aberrant/
likely aberrant group (57/121) and 80% for the UNK group 
(12/15). The workup of the newborn babies who tested “nor-
mal/likely normal” did not yield discrepant results. The UNK 
samples without follow-up all belonged to the first data set and 
were from newborns who were born healthy (composite fol-
low-up of UNK samples 15/15 or 100%). For T21, there were 
the following discrepancies (henceforth designated as “FPs” or 
“FNs”): four false positives (FPs) and no false negatives (FNs); 
two FNs and no FP for T18; and four FPs and no FN for tri-
somy 13 (Table 1). Thus, the estimates for the false-positive 
rates (FPRs; Table 1) were 0.063% for T21, <0.001% for T18, 
and 0.062% for T13. The detection rates (DRs; Table 1) were 
>99.99% for T21 and T13 (84/84 and 16/16, respectively) and 
approximately 90% for T18 (17/19). Three out of three with 
UNK status for chromosome 21 and four out of four with UNK 
status for chromosome 13 turned out to be normal diploids. Six 
out of eight with UNK status for chromosome 18 turned out 
to be normal diploids, of which two babies were born healthy 
without aneuploidy and two had false-negative results.
The reasons for the two FNs for T18 were low fetal fraction in 
one case and likely TFM5 for the other case. Both samples were 
in the first data set, before introduction of routine fetal fraction 
measurements. The first FN with a fetal fraction of 3.7% and 
native z-score of 3.1 showed complete and specific rescue of an 
abnormal T18 signal after cfDNA enrichment to 33.4% with a 
z-score of 7.2; the T18 signal of the second FN with a native fetal 
fraction of 9.5% and z-score of 2.9, however, stayed close to, 
but did not cross the threshold even after enrichment to 28.5% 
and a z-score 2.7. A similar enrichment of euploid samples did 
not generate FP T18 results. The first FN was therefore caused 
by low fetal fraction. For the second, there was only a limited 
amount of cfDNA molecules with T18 available in the circulat-
ing blood, indicating TFM5.
Low z-scores in the presence of average fetal fractions 
were the best predictor of FPs. Overall there were eight FPs: 
four for T21, four for T13, and none for T18. The key differ-
ence between true positives (TPs) and FPs is that TPs (n = 10) 
had significantly higher z-scores than the FPs (n = 7) yet 
similar fetal fractions (z-scores and fetal fractions for TPs/
FPs were 15.6 ± 3.7/4.97 ± 0.79 (t-test P < 0.0001) and 
11.6 ± 1.91%/10.2 ± 1.75% (P = 0.1623)). One FP for T21 was 
indistinguishable from TPs based solely on the z-score of 29.8 
and the fetal fraction of 25%.
If low-grade placental confined mosaicism (CPM) is the 
principal reason for FPs, then the trisomy z-scores will increase 
only marginally, even for maximal fetal fractions of 50%, and 
this is exactly what was found. For five FPs, the fetal fraction 
was enriched from 10.28 ± 1.56% to 51.08 ± 8.2% (P < 0.0001) 
and the corresponding z-scores moved from 5.11 ± 0.93 to 
7.74 ± 2.97 (P = 0.0964). For one single FP with an initial 
z-score of 29.8, the enrichment from 25% to 56.7% moved the 
z-score to 54.25. This indicates that low z-scores as a proxy for 
low-grade CPMs are a more frequent cause of FPs than high 
z-scores as proxy for high-level mosaicism, provided that the 
fetal fractions are comparable and average for both, in accor-
dance with predictions based on CVS data.12,24–26
For two FPs, however, the z-score was not increased (0.7 
and 1.58) despite significant augmentation of the fetal frac-
tion from 12.6 to 60.8% and from 11.1 to 54.6%. For the latter 
two, a technical problem (i.e., signal variance) is the most likely 
explanation.
Fifty-three cases (0.83%; 53/6,388) of SCAs were found 
(Figure 1): 38 (71%) with monosomy X (MX), 10 (18.9%) with 
triple X syndrome (TXS), and 5 (9.4%) with Klinefelter syn-
drome (KS). Inversely, 99.17% of samples had a physiological 
sex-chromosome dosage. Of the 38 MX cases, 32 were classified 
as abnormal and 6 were classified as likely abnormal. Four out 
of those 32 considered abnormal had z-scores largely superior 
(P < 0.001) to those obtained for the highest fetal fractions, sug-
gesting maternal MX mosaicism. The four candidate maternal 
MX cases had fetal fractions and z-scores of 8.8% ± 4.25 and 
−30.7 ± 11.11. Compared to the confirmed exclusively fetal ref-
erence MX cases (n = 15; z-scores −9.28 ± 3.56), the values for 
the candidate maternal MX mosaicism cases are expected to 
occur for less than one in a million exclusively fetal cases with 
45,X (z-scores <−26.7). All 10 TXS and all 5 KS were considered 
Table 1 Test performance for major trisomies
Aneuploidy (n) DR sensitivity (95% CI) FPR 1 specificity (95% CI) PPV (95% CI) NPV (95% CI)
Trisomy 21 (84) >99.99% (94.29–100) 0.063%b (0.17–0.02) 95.23%b (87.59–98.46) >99.99% (99.92–100)
Trisomy 18 (19) 90%a (66.87–98.24) <0.001% (0.07–0.00) >99.99% (78.12–100) 99.96% (99.87–99.99)
Trisomy 13 (16) >99.99% (69.87–100) 0.062%c (0.17–0.02) 75.0%c (47.4–91.66) >99.99% (99.92–100)
The DRs and false-positive rates (FPRs) as well as positive predictive value (PPV) and negative predictive value (NPV) expressed in percentages with 95% confidence intervals 
in parentheses.
aOne of two false negatives (FNs) would be avoided with the current test conditions, leading to a detection rate (DR) of 94.73%. b,cSeven of the eight total false positives 
could be predicted and potentially avoided under the current test conditions.
CI, confidence interval.
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abnormal. One TXS had a z-score largely exceeding those of the 
highest fetal fractions, indicating maternal TXS. The z-scores 
for the validated fetal reference 47,XXX cases were 12.1 ± 2.29 
(n = 5) and the candidate maternal 47,XXX case had a z-score 
of 75.3; such values are expected for less than one in a trillion 
cases with purely fetal 47,XXX (z-scores >28.4).
Follow-up with amniocentesis was 63% (24/38) for MX, 40% 
(4/10) for KS, and 20% (1/5) for TXS. The inquiry of suspected 
newborns did not reveal clinically evident cases present at birth 
or the presence of classic Turner syndrome. Specifically, three 
potential MX cases were followed up at birth, two FPs with nor-
mal postnatal karyotype 46,XX and one UNK who was clini-
cally unsuspicious (total follow-up: 27/39, 69%). There were no 
known FNs and 17 FPs for MX, and no known FNs and FPs for 
TXS and KS (Supplementary Table S1 online).
Low z-scores concomitant with average fetal fractions were—
similar to the common trisomy group—a reliable predictor of 
FPs. This is supported by the following lines of evidence: (i) the 
likelihood of confirming a positive 45,X test result with amnio-
centesis increases with the z-score as a proxy for the degree of 
mosaicism—the z-scores and fetal fractions of TPs (n = 5)/
FPs (n = 6) were −10.12 ± 1.43/−5.28 ± 1.47 (P = 0.0004) and 
15.8 ± 9.7%/13.9 ± 2.9%; (ii) specifically and strongly increased 
z-scores after a second blood draw or experimental fetal cfDNA 
enrichment are predictive of TPs after amniocentesis (z-scores 
and fetal fractions for first/second blood draw were −4.26/−9.36 
and 5.6%/15.3%, and before/after fetal cfDNA enrichment 
were −6.14/−12.4 and 8.6%/29.7%, respectively); (iii) 15 out 
of 15 clinically affected 45,X cases were all correctly called 
in a blinded fashion during our technical validation study.22 
Globally, the likelihood of positive cfDNA 45,X test calls to be 
confirmed by amniocentesis is largely dominated by biological 
parameters, of which CPM is the single most important one, as 
predicted by CVS data.12,24–26
The higher prevalence of FPs for MX compared to the other 
SCA and common trisomies is expected because the CPM1/3 
rate is much higher, approximately 60% for MX and mosaicism 
levels exceeding 50%.26 This fully accounts for the positive pre-
dictive value (PPV) of 55% observed for MX (Supplementary 
Table S1 online). The FPR for MX is 0.26%, the FPRs for the 
other SCAs for both KS and TXS are <0.01%. The DRs for the 
SCAs were nominally >99.9%, specifically 21/21 for MX (9/9 
directly validated), 10/10 for KS, and 5/5 for TXS. This excludes 
only mosaic aneuploidies that are clinically detectable at birth.
In the RAT group, 50 cases were found (50/6,388, 0.78%; 
Figure 2). These are listed individually in Figure 2: the most 
frequent (32%) was T7, with 16 cases that could be associated 
with UPD.14 The group with a high or very high risk for an unfa-
vorable outcome if the fetus were affected13 comprised seven 
cases (14%). Trisomy cases potentially associated with UPD, 
namely T6, T7, T14, T15, and T16, were considered abnormal 
or likely abnormal because UPD can be symptomatic even in 
diploid fetuses after trisomy or monosomy rescue.14 All other 
trisomies were rated abnormal or likely abnormal based on the 
relative evidence for further workup.6,13 Overall, 35 out of 50 
(70%) trisomies were considered abnormal, and 15 (30%) were 
considered likely abnormal.
The follow-up with amniocentesis was 38% for the group as 
a whole (19/50) and focused on critical groups, for instance: 
100% (3/3) for trisomy 22, 50% (2/4) for trisomy 16, and 37.5% 
(6/16) for T7, which included routine molecular UPD analysis 
in addition to karyotyping. Four fetal aneuploidies were con-
firmed; all three T22 mosaicism cases were fetal, as was one 
case of T12 mosaicism. For all remaining cases, amniocente-
sis revealed normal diploid results; in the cases with potential 
UPD, no single fetal UPD was identified. This resulted in a 
nominal FPR of 0.71% and a low PPV of 8%.
Several lines of evidence support the notion that these low 
PPVs reflect primarily CPM24 rather than technical problems. 
First, the z-scores between the TPs and FPs did not signifi-
cantly differ. We compared the TPs, three with T22 and one 
with T12 mosaicism, with the FPs comprising the trisomies 
having the highest risk for an unfavorable outcome,13 namely 
T7, T9, T16, and T20. The z-scores and fetal fractions of TPs/
FPs were not significantly different: 12 ± 3.8/10.72 ± 6.42 
(P  =  0.73) and 11.05 ± 2.16%/11.17 ± 4.25% (P = 0.95). 
Second, stronger increases in z-scores on cfDNA enrichment 
than those observed for the FPs of the common trisomies 
were observed (z-score and fetal fraction native/enriched 
were 5.18/11.91 and 5.8%/55.3%). For predicted cases of 
T16 mosaicism, a consistent rate of unfavorable pregnancy 
outcome was observed (25%) as expected.15 The technical 
validation study had proven highly accurate detection of this 
class of anomalies.22
Thirty-six candidate CNVs were identified, 25 in the first data 
set and 11 in the second data set (0.56%) (Table 2). All were 
rated pathogenic or likely pathogenic without clear-cut distinc-
tion because of the difficulty of integrating multiparametric 
factors such as the critical regions, size, penetrance, and inheri-
tance. Copy-number variation in two genomic regions known 
to undergo recurrent rearrangements and to overlap with well-
known genomic disorders were more frequently found, namely, 
two deletions and two duplications of the DGS region 22q11.2 
Figure 2 The detected individual rare autosomal trisomies. The 
absolute numbers of the individual rare autosomal trisomies are shown from 
left to right in decreasing order of frequency found.
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(11%) and two deletions and two duplications of the 16p13.11 
critical region (11%) (Table 2).17 Other recurrent CNVs were 
identified, such as two duplications of the 15q11.2 region and 
one duplication of the 17p12 region (Table  2). Nonrecurrent 
CNVs not estimated to overlap with known genomic disorders 
are listed in Table 2.
For 11/36 (30.5%), follow-up data with chromosomal micro-
array and/or FISH analysis after amniocentesis and parental 
analyses were available. For the recurrent CNVs with defined 
pathogenicity, the follow-up was nearly complete; specifically, 
it was available for 3/4 CNVs of the 22q11.2 region and for 3/4 
CNVs of the 16p13.11, as well as for the duplication of 17p12 
(PMP22). The following maternally transmitted CNVs were all 
confirmed in mother and fetus: two duplications and one dele-
tion of 22q11.2, one duplication and one deletion of 16p13.11, 
and one duplication of 17p12. In the nonrecurrent CNV class, 
a maternally transmitted deletion of 9q31 was confirmed in 
mother and fetus. Overall, three candidate CNVs were not 
confirmed: one of the deletions of 16p13.11 and, in the non-
recurrent CNV class, a deletion of 5q14.3q23.2 and a deletion 
of 10q22-q33, totaling three FP results. During the follow-up 
of pregnancies in the first data set, prior to fetal fraction mea-
surements, a 10-Mb terminal deletion of 4p had not been called 
(one FN result).
Based on this experience, the analytical DRs were defined 
experimentally for recurrent CNVs of defined size and as a 
function of the fetal fraction (Figure 3). These experiments 
indicate a robust detection of CNVs with a size class of 3 Mb 
for the most frequently implicated region, 22q11.2, and an aver-
age range of fetal fractions of 10%. Accordingly, we recommend 
limiting the clinical use to detection of recurrent CNVs of 
defined size and penetrance17 for which the DR can be defined 
with the use of positive controls and depending on the fetal 
fraction.
Table 2 CNVs overlapping or not with genomic disorders
CNVs not overlapping with genomic disorders Data set (n) CNVs overlapping with genomic disorders Data set (n)
Chromosomal region Breakpoints (hg19) 1st/2nd Chromosomal region Breakpoints (hg19) 1st/2nd
HSA1:dup 1p31 (69,975,000–74,425,000) 1 HSA15:dup 15q11.2 (20,175,000–26,575,000) 1
HSA15:dup 15q11.2 (20,175,000–29,925,000) 1
HSA2:dup 2q24.3 (16,500,001–20,300,001) 1
HSA16:del 16p13.12 (13,175,000–19,475,000)  
(13,925,000–19,925,000)
1 1
HSA3:del 3p26.1 (0–3,200,000) 1 HSA16:dup 16p13.12 
(14,025,000–19,825,000)
2
HSA3:dup 3p14 (64,850,000–68,700,000) 1
HSA17:dup 17p12 (12,625,000–17,275,000) 1
HSA4:dup 4q13 (59,150,000–63,500,000) 1
HSA4:dup 4q21-22 (68,300,000–73,050,000) 1 HSA22:del 22q11.2 (17,175,000–22,100,000)  
(17,175,000–25,375,000)
1 1
HSA4:dup 4q?3 (149,500,000–154,200,000) 1 HSA22:dup 22q11.2 (17,175,000–23,125,000)  
(17,175,000–23,175,000)
1 1
HSA4:dup 4q35 (186,550,000–190,875,000) 1
HSA4:del 4q33 (187,150,000–190,875,000) 1
HSA5:dup 5p15.2 (20,300,000–25,050,000) 1
HSA5:del 5q14.3 (90,250,000–126,750,000) 1
HSA7:dup 7q21 (86,975,000–90,975,000) 1
HSA8:dup 8p23.3 (3,025,000–6,675,000) 1
HSA8:del 8p23 (14,175,000–18,775,000) 1
HSA9:dup 9p21.1 (28,250,000–32,450,000) 1
HSA9:del 9q31 (102,550,000–107,150,000) 1
HSA9:dup 9q22 (103,750,000–107,450,000) 1
HSA10:dup 10q?11 (43,900,000–52,225,000) 1
HSA10:del 10q22 (63,950,000–68,600,000) 1
HSA10:dup 10q25.3 (118,200,000–129,650,000) 1
HSA13:dup 13q12 (19,500,000–26,450,000) 1
HSA15:dup 15q13.1 (28,175,000–34,425,000) 1
HSA17:del 17p12 (12,775,000–17,375,000) 1
HSA17:dup 17q24.3 (70,225,000–74,725,000) 1
HSA20:dup 20p12.3 (7,025,000–11,325,000) 1
Nonrecurrent CNVs are listed according to individual chromosome (HSA) and breakpoints given in parentheses (hg19). dup, duplications; del, deletions. Recurrent CNVs are 
listed according to individual chromosome (HSA) and breakpoints given in parentheses (hg19). 
CNV, copy-number variations.
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DIsCUssION
Here, we reviewed the follow-up of a series of 6,388 consecutive 
clinical cases using cfDNA screening with low genomic cover-
age and detected a broad range of aneuploidy classes, namely 
the common trisomies, the SCA, the RATs, and deletion and 
duplication CNVs.
Clinical follow-up amniocentesis results considered abnor-
mal, likely abnormal, or UNK were between 30 and 80% for 
the four aneuploidy categories (mean, 42.5 ± 10.8%). It was 
generally close to complete—between 75 and 80%—for results 
considered UNK and when maternal mosaicism was suspected. 
Follow-up for results classified as normal or likely normal was 
ensured by an online birth registry, by an inquiry of randomly 
selected samples, and by proximity to the addressing physi-
cians. These follow-up figures typically are higher than those 
reported in the literature, especially for the UNK group.
In comparison with the most recently updated meta-anal-
ysis,1 we report both very high DRs and very low FPRs for 
the common trisomies. Overall, only two FNs were recorded 
(both for T18): one caused by a low fetal fraction that would 
be avoided under current conditions and the other due to 
likely TFM5. A lower DR for T18 compared to T21 and T13 
is exactly what is expected because of the higher TFM rate for 
T18 based on CVS data.26 The workup of the eight FPs for T21 
and T13 showed that low z-scores as a proxy for likely low-
grade CPMs are more frequently producing FPs than high 
z-scores as a proxy for high-level mosaicism, provided there 
are comparably normal fetal fractions. These findings, again, 
precisely reflect the predictions of CVS data that relate four 
times more FPs to low-grade than high-grade trisomy mosa-
icism.12,24-26 We did not find any evidence of maternal CNVs 
as potential confounding factors, as reported by a number of 
studies.2,23,27,28 The proportion of FPs explained by a demis-
ing twin is difficult to access because there is no systematic 
measurement of the number of heartbeats in early pregnancy. 
The key conclusions are, first, that the specific nature of FNs 
(low fetal fraction versus TFM5) and, second, the likelihood 
of FPs can be predicted based on z-scores, fetal fraction, and 
cfDNA enrichment.
Parallel evidence is provided for the accurate detection of 
SCAs, consistent with our technical validation study dem-
onstrating performance similar to the common trisomies.1,22 
In accordance with the predictions of CVS data;24,26 however, 
CPM was responsible for a significant proportion of FPs likely 
accounting for 37% of all MX results. Vanishing twins again 
constitute a mystifying cause that could not be safely dissoci-
ated from placental mosaicism. Interestingly, 3 out of the 17 
FPs comprising 7.9% of all MXs were likely due to maternal 
MX mosaicism, based on two lines of evidence: (i) exceedingly 
high z-scores incompatible with those expected for purely 
fetal affections and (ii) although these three cases were not 
worked-up, a sample indistinguishable from the three based 
on the z-scores and fetal fraction was shown to correspond 
to 14% maternal MX mosaicism (mos 45,X[7]/46,XX[43]). 
In conclusion, detection of SCAs presents evidence similar 
to that of the common trisomies, provided that (i) an ade-
quate technical validation study is corroborated by clinical 
follow-up programs; (ii) detection is limited to aneuploidies 
with evidence-based workup; and (iii) women are counseled 
appropriately because of higher CMP rates and significant risk 
of detecting maternal mosaicism.
Based on the current data series, we suggest that detection of 
RATs is clinically useful for at least five reasons: (i) the accuracy 
was similar to that of the common trisomies and SCAs22; (ii) the 
PPVs closely reflected those predicted by CVS data;13 (iii) T22 
mosaicism is an important cause of truly fetal aneuploidy; (iv) 
although UPD cases were not detected in the present study, this 
reflects prevalence data;13 and (v) even without UPD, placen-
tal mosaicism carries a small but definite risk for intrauterine 
growth restriction, small-for-gestational-age infants, and unfa-
vorable pregnancy outcome (e.g., T16), which is supported by 
this study.15
We initially designed CNV detection to be genome-wide in 
principle. The experience with these data set clearly revealed 
the limitations of such an approach; for most, if not all, non-
recurrent CNVs, solid and reliable data on allele frequencies, 
segregation, implicated genes and pathways, and phenotypic 
consequences are lacking, which makes clinical implemen-
tation in a prenatal setting problematic. For this reason, the 
diagnostic workup of recurrent CNVs was emphasized. This 
experience clearly showed that this subclass of CNVs can be 
robustly detected in the context of a routine clinical program. 
Specifically, spike-in experiments (Figure 3) using positive 
control cfDNA allowed the detection sensitivity to be defined 
for CNV size classes dependent on the fetal fraction. Similar 
to what we described for the SCAs, the signal intensity could 
also be used to predict whether a CNV is maternally transmit-
ted. Consequently, such predictions can be implemented to 
prevent false-positive CNV calling.27
Figure 3 standardization of detection of Di George syndrome 
duplication. Average (±1 SD) signal intensities of the negative control (left) 
and of serial dilutions (from left to right: 5%, 10%, 15%, 20%, 25%) of 
the chromosomal microarray-validated fetal case of maternal origin with a 
3-Mb duplication of 22q11.2 (shown as 100% dosage on the far right). 
The detection thresholds are shown as dashed lines, the lower line represents 
the 99% confidence level (z-score +2.575829), and the upper line reflects the 
99.9% confidence level (z-score +3.290527).
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The following recommendations can be made based on 
the present study: (i) cfDNA screening should be extended 
to include detection of RATs and deletion/duplication-CNVs; 
(ii) integrated interpretation of the fetal fraction, z-scores, and 
fetal cfDNA enrichment should be used to stratify the likeli-
hood of FNs/FPs caused by CPM and maternal aneuploidy/
CNVs; and (iii) CNV detection should be based on experi-
mental validation of defined CNV size classes integrating the 
fetal fraction and should be limited to a list of well-character-
ized genomic disorders. The latter can be expanded with the 
increasing knowledge base. Extensions of the present study 
could comprise targeted high-coverage sequencing to more 
closely investigate UPD and the potential recessive unmask-
ing associated with it, as well as to search for frequent single-
gene disorders in the future.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim
ACKNOWLEDGMENTS
We thank Franz Binkert, Peter Kuhn, Alexandre Reymond, and 
Simon Rothen for discussions, the diagnostic team members for 
their devoted daily routine commitment, namely, Erika Duval, 
Ursula Weber, Ruth Schweizer, Antonio Chiacchio, Marion Krüger, 
Marco Belfiore, Nathalie Roussy, Emina Sunj, Daniel Robyr, Char-
lotte Sillacci, Cécile Deluen, Julien Schira, Nadine Vincent, Cristel 
Busca, Vianney Frigard, Marta Cotado, and Loïc Baerlocher, as 
well as the informatics team members, including Yves Babitch, 
Flavien Ombelli, and Francis Perrelet.
DISCLOSURE
G.P., M.O., L.F., and B.C. are minority shareholders of Sonic 
Healthcare, which owns Aurigen, Fasteris, and Genesupport. The 
other authors declare no conflict of interest.
REFERENCES
 1. Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH. Analysis of cell-
free DNA in maternal blood in screening for fetal aneuploidies: updated meta-
analysis. Ultrasound Obstet Gynecol 2015;45:249–266.
 2. Zhang H, Gao Y, Jiang F, et al. Non-invasive prenatal testing for trisomies 21, 
18 and 13: clinical experience from 146,958 pregnancies. Ultrasound Obstet 
Gynecol 2015;45:530–538.
 3. McCullough RM, Almasri EA, Guan X, et al. Non-invasive prenatal chromosomal 
aneuploidy testing–clinical experience: 100,000 clinical samples. PLoS One 
2014;9:e109173.
 4. Bianchi DW, Parsa S, Bhatt S, et al. Fetal sex chromosome testing by maternal 
plasma DNA sequencing: clinical laboratory experience and biology. Obstet 
Gynecol 2015;125:375–382.
 5. Davis C, Cuckle H, Yaron Y. Screening for Down syndrome–incidental diagnosis 
of other aneuploidies. Prenat Diagn 2014;34:1044–1048.
 6. Wellesley D, Dolk H, Boyd PA, et al. Rare chromosome abnormalities, prevalence 
and prenatal diagnosis rates from population-based congenital anomaly 
registers in Europe. Eur J Hum Genet 2012;20:521–526.
 7. Lebo RV, Novak RW, Wolfe K, Michelson M, Robinson H, Mancuso MS. 
Discordant circulating fetal DNA and subsequent cytogenetics reveal false 
negative, placental mosaic, and fetal mosaic cfDNA genotypes. J Transl Med 
2015;13:260.
 8. Tørring N, Petersen OB, Becher N, Vogel I, Uldbjerg N; Danish Fetal Medicine 
Study Group; Danish Clinical Genetics Study Group. First trimester screening for 
other trisomies than trisomy 21, 18, and 13. Prenat Diagn 2015;35:612–619.
 9. Grande M, Jansen FA, Blumenfeld YJ, et al. Genomic microarray in fetuses with 
increased nuchal translucency and normal karyotype: a systematic review and 
meta-analysis. Ultrasound Obstet Gynecol 2015;46:650–658.
 10. Neufeld-Kaiser WA, Cheng EY, Liu YJ. Positive predictive value of non-invasive 
prenatal screening for fetal chromosome disorders using cell-free DNA in 
maternal serum: independent clinical experience of a tertiary referral center. 
BMC Med 2015;13:129.
 11. Kalousek DK, Pantzar T, Tsai M, et al. Pathology of abortion: chromosomal and 
genetic correlations. Monogr Pathol 1991; 33: 228–256.
 12. Malvestiti F, Agrati C, Grimi B, et al. Interpreting mosaicism in chorionic villi: 
results of a monocentric series of 1001 mosaics in chorionic villi with follow-up 
amniocentesis. Prenat Diagn 2015;35:1117–1127.
 13. Wallerstein R, Misra S, Dugar RB, Alem M, Mazzoni R, Garabedian MJ. Current 
knowledge of prenatal diagnosis of mosaic autosomal trisomy in amniocytes: 
karyotype/phenotype correlations. Prenat Diagn 2015;35:841–847.
 14. Eggermann T, Soellner L, Buiting K, Kotzot D. Mosaicism and uniparental 
disomy in prenatal diagnosis. Trends Mol Med 2015;21:77–87.
 15. Robinson WP, Peñaherrera MS, Jiang R, et al. Assessing the role of placental 
trisomy in preeclampsia and intrauterine growth restriction. Prenat Diagn 
2010;30:1–8.
 16. Sudmant PH, Mallick S, Nelson BJ, et al. Global diversity, population 
stratification, and selection of human copy-number variation. Science 
2015;349:aab3761.
 17. Cooper GM, Coe BP, Girirajan S, et al. A copy number variation morbidity map 
of developmental delay. Nat Genet 2011;43:838–846.
 18. Jensen TJ, Dzakula Z, Deciu C, van den Boom D, Ehrich M. Detection of 
microdeletion 22q11.2 in a fetus by next-generation sequencing of maternal 
plasma. Clin Chem 2012;58:1148–1151.
 19. Srinivasan A, Bianchi DW, Huang H, Sehnert AJ, Rava RP. Noninvasive detection 
of fetal subchromosome abnormalities via deep sequencing of maternal 
plasma. Am J Hum Genet 2013;92:167–176.
 20. Zhao C, Tynan J, Ehrich M, et al. Detection of fetal subchromosomal 
abnormalities by sequencing circulating cell-free DNA from maternal plasma. 
Clin Chem 2015;61:608–616.
 21. Helgeson J, Wardrop J, Boomer T, et al. Clinical outcome of subchromosomal 
events detected by whole-genome noninvasive prenatal testing. Prenat Diagn 
2015;35:999–1004.
 22. Guex N, Iseli C, Syngelaki A, et al. A robust second-generation genome-
wide test for fetal aneuploidy based on shotgun sequencing cell-free DNA in 
maternal blood. Prenat Diagn 2013;33:707–710.
 23. Bayindir B, Dehaspe L, Brison N, et al. Noninvasive prenatal testing using a 
novel analysis pipeline to screen for all autosomal fetal aneuploidies improves 
pregnancy management. Eur J Hum Genet 2015;23:1286–1293.
 24. Grati FR, Grimi B, Frascoli G, et al. Confirmation of mosaicism and uniparental 
disomy in amniocytes, after detection of mosaic chromosome abnormalities in 
chorionic villi. Eur J Hum Genet 2006;14:282–288.
 25. Grati FR, Molina Gomes D, Ferreira JC, et al. Prevalence of recurrent pathogenic 
microdeletions and microduplications in over 9500 pregnancies. Prenat Diagn 
2015;35:801–809.
 26. Grati FR, Malvestiti F, Ferreira JC, et al. Fetoplacental mosaicism: potential 
implications for false-positive and false-negative noninvasive prenatal screening 
results. Genet Med 2014;16:620–624.
 27. Snyder MW, Simmons LE, Kitzman JO, et al. Copy-number variation and 
false positive prenatal aneuploidy screening results. N Engl J Med 2015;372: 
1639–1645.
 28. Brady P, Brison N, Van Den Bogaert K, et al. Clinical implementation of NIPT - 
technical and biological challenges. Clin Genet 2016;89:523–530.
This work is licensed under a Creative Commons 
Attribution-NonCommercial-ShareAlike 4.0 
International License. The images or other third party 
 material in this article are included in the article’s Creative 
Commons license, unless indicated otherwise in the credit 
line; if the material is not included under the Creative 
 Commons license, users will need to obtain permission from 
the license holder to reproduce the material. To view a copy 
of this license, visit http://creativecommons.org/licenses/ 
by-nc-sa/4.0/
© G Pescia et al. (2016)
GeNeTICs in MeDICINe  |  Volume 19  |  Number 2  |  February 2017
